Renaissance Technologies
RANI icon

Renaissance Technologies’s Rani Therapeutics RANI Stock Holding History

Renaissance Technologies’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,908
Closed -$12.4K – 3667
2025
Q3 		$12.4K Buy
+24,908
New +$13K ﹤0.01% 3445
2024
Q4 		– Sell
-33,199
Closed -$71.7K – 3846
2024
Q3 		$71.7K Buy
33,199
+11,499
+53% +$32.9K ﹤0.01% 3307
2024
Q2 		$82.5K Sell
21,700
-48,600
-69% -$252K ﹤0.01% 3218
2024
Q1 		$219K Buy
70,300
+26,600
+61% +$91.5K ﹤0.01% 3199
2023
Q4 		$145K Sell
43,700
-7,300
-14% -$16.9K ﹤0.01% 3220
2023
Q3 		$111K Sell
51,000
-37,201
-42% -$142K ﹤0.01% 3224
2023
Q2 		$363K Buy
88,201
+47,084
+115% +$219K ﹤0.01% 3040
2023
Q1 		$212K Buy
41,117
+2,717
+7% +$16.3K ﹤0.01% 3255
2022
Q4 		$227K Buy
+38,400
New +$280K ﹤0.01% 3363

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Renaissance Technologies's RANI Position: Q4 2025 in Review

Renaissance Technologies sold out of Rani Therapeutics (RANI) in Q4 2025, closing a stake of 24,908 shares — an estimated $12.4K sold.

Renaissance Technologies first reported a position in RANI in Q4 2022 and held it in 9 quarters. The position peaked at $363K in Q2 2023. 64 funds tracked by Wall St. Rank hold RANI as of Q4 2025.

  • Renaissance Technologies reported no remaining Rani Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 24,908 Rani Therapeutics shares in Q4 2025, an estimated $12.4K.
  • Renaissance Technologies first reported a position in Rani Therapeutics in Q4 2022 and held it in 9 quarters.
  • Renaissance Technologies's Rani Therapeutics position peaked at $363K in Q2 2023.
  • 64 funds tracked by Wall St. Rank held Rani Therapeutics as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.